Cancer remains the second leading cause of death worldwide, surpassed only by
cardiovascular disease. From the different types of cancer, pancreatic cancer (PaC) has one …

Neoadjuvant therapy is increasingly used to treat patients with pancreatic ductal
adenocarcinoma (PDAC). Pathologic parameters of treated PDAC, including tumor (ypT) …

Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors
and approximately 5% of patients with chronic pancreatitis (CP) inevitably develop PDAC …

Simple Summary This study is to examine the clinical and pathologic characteristics and
survival in patients who received neoadjuvant FOLFINOX or neoadjuvant gemcitabine/nab …

Purpose Pancreatic ductal adenocarcinoma (PDAC) frequently presents as hypo-or iso-
dense masses with poor contrast delineation from surrounding parenchyma, which …

Abstract Background Pancreatic cancer (PaCa) is one of the most intractable and fatal
malignancies and is associated with the dysregulation of long noncoding RNAs (lncRNAs) …

This study aimed to evaluate and compare the predictive performance of negative lymph
nodes (NLN), lymph node ratio (LNR), and N stage in pancreatic ductal adenocarcinoma …

Background/objectives The aim of our study was to evaluate if the histopathological changes
occurring in the pancreas post neoadjuvant-therapy (PNAT) for pancreatic ductal …

In this series “Pre-and post-operative treatment for pancreatic cancer”, we publish four
insightful narrative reviews by the experts from medical oncology, surgical oncology, and …

Die Pankreaspathologie befindet sich in stetiger Weiterentwicklung und hält viele
Herausforderungen für Pathologinnen und Pathologen bereit. Der Fokus dieser …